Beam Therapeutics
BEAM
277 hedge funds and large institutions have $3.75B invested in Beam Therapeutics in 2026 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 94 increasing their positions, 76 reducing their positions, and 31 closing their positions.
230% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $6.94M
90% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 31
46% more capital invested
Capital invested by funds: $2.58B → $3.75B (+$1.17B)
24% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 76
9% more funds holding
Funds holding: 253 → 277 (+24)
0.02% more ownership
Funds ownership: 106.31% → 106.33% (+0.02%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$39.3M |
| 2 |
CGH
Contrarius Group Holdings
Hamilton,
Bermuda
|
+$32.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.2M |
| 4 |
BlackRock
New York
|
+$15.4M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$57.3M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$34.5M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$26.9M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$25.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$16M |
BEAM Hedge Fund Activity: Q2 2026 in Review
277 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2026, worth a combined $3.75B — up 46% from $2.58B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new BEAM positions and 31 closed out — a net gain of 28 holders — while 94 added to existing stakes and 76 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $39.3M. The largest seller was ARK Investment Management, cutting an estimated $57.3M.
- 277 institutional investors held Beam Therapeutics (BEAM) as of Q2 2026, up from 253 in Q1 2026.
- Funds reported $3.75B of Beam Therapeutics stock for Q2 2026, up 46% quarter-over-quarter.
- 59 funds opened new Beam Therapeutics positions in Q2 2026 and 31 closed out, a net change of +28 holders.
- The largest Beam Therapeutics buyer in Q2 2026 was Morgan Stanley, an estimated $39.3M added.
- The largest Beam Therapeutics seller in Q2 2026 was ARK Investment Management, an estimated $57.3M sold.
Based on aggregated 13F filings for Q2 2026.